Korro Bio, Inc. short interest in 2023
In 2023, Korro Bio, Inc.'s disclosed short interest ran from 1.37% of shares outstanding on 13 Jan 2023 to 1.39% on 31 Oct 2023, a change of +0.02 percentage points. The year's high was 4.70% on 31 Jul 2023 and its low 1.00% on 13 Oct 2023, averaging 2.13% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.67 days on 15 Jun 2023. Full history: Korro Bio, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.37% (13 Jan 2023)
- End of year
- 1.39% (31 Oct 2023)
- Change
- +0.02 pp
- High
- 4.70% (31 Jul 2023)
- Low
- 1.00% (13 Oct 2023)
- Average
- 2.13%
- Highest days to cover
- 6.67 (15 Jun 2023)
- SEC filings marked
- 9
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.37% | 1.39 | |
| 31 Jan 2023 | 2.23% | 2.19 | |
| 15 Feb 2023 | 3.67% | 1.00 | results (8-K) |
| 28 Feb 2023 | 1.54% | 1.00 | |
| 15 Mar 2023 | 1.23% | 1.00 | 10-K filed, results (8-K) |
| 31 Mar 2023 | 2.39% | 2.10 | |
| 14 Apr 2023 | 2.51% | 2.77 | |
| 28 Apr 2023 | 2.74% | 5.32 | |
| 15 May 2023 | 2.14% | 6.10 | 10-Q filed, results (8-K) |
| 31 May 2023 | 1.95% | 6.20 | |
| 15 Jun 2023 | 2.14% | 6.67 | |
| 30 Jun 2023 | 2.51% | 5.67 | |
| 14 Jul 2023 | 2.73% | 1.00 | |
| 31 Jul 2023 | 4.70% | 1.15 | |
| 15 Aug 2023 | 2.40% | 1.64 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 1.46% | 2.96 | |
| 15 Sep 2023 | 1.41% | 4.75 | |
| 29 Sep 2023 | 1.09% | 5.13 | |
| 13 Oct 2023 | 1.00% | 2.75 | |
| 31 Oct 2023 | 1.39% | 2.99 |
See also: Korro Bio, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.